trial with title COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US

*Study enrollment impact due to Coronavirus (COVID-19)*

Please note that some study locations are now accepting new study participants, however some locations remain closed due to the ongoing impact of Coronavirus (COVID-19). Please continue to check back as we expect to add more study locations as this situation improves and changes.

Who is eligible to participate?

The COMMANDS Trial may be an option for those who meet the following criteria:
• Are 18 years of age and older
• Have been diagnosed with MDS with anemia
• Require blood cell transfusions

If you meet these initial criteria, we invite you to take the prescreening questionnaire to see if you may qualify to participate in this study.

Check if you are eligible Enter contact details Select a site

Have you been diagnosed with myelodysplastic syndromes (MDS)?

For more information, please watch the video.

Participation in the study lasts approximately six years (and may be shorter or longer for certain patients). This includes:

• a screening period of approximately 35 days,
• an initial 24-week treatment period (which may be extended if certain criteria are met and if you continue to benefit from the treatment), and
• a follow-up period where you will be contacted approximately every 12 weeks to ask how you are doing. 

The study drug being used in the COMMANDS Trial is called luspatercept, which is a protein that aims to help increase the production of red blood cells in bone marrow. Luspatercept will be administered as an injection every three weeks during the treatment period.